A retrospective study to evaluate the Pirfenidone dose adjustment by body weight/surface area in patients with Interstitial Pneumonia and idiopathic pulmonary fibrosis

Trial Profile

A retrospective study to evaluate the Pirfenidone dose adjustment by body weight/surface area in patients with Interstitial Pneumonia and idiopathic pulmonary fibrosis

Completed
Phase of Trial: Phase IV

Latest Information Update: 29 Aug 2017

At a glance

  • Drugs Pirfenidone (Primary)
  • Indications Idiopathic pulmonary fibrosis; Interstitial lung diseases
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 29 Aug 2017 Results published in the Respirology.
    • 13 Jul 2017 New trial record
    • 24 May 2017 Results presented at the 113th International Conference of the American Thoracic Society
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top